The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

Overview of attention for article published in Arthritis Research & Therapy, February 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter: 4 X users
patent: 2 patents

facebook: 2 Facebook pages

Citations

dimensions_citation: 54 Dimensions

Readers on

mendeley: 46 Mendeley

Summary X Patents Facebook Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

HETEROCYCLIC COMPOUND

Application WO-2024033845-A1

World Intellectual Property Organisation (WIPO)

FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS

Application WO-2023194964-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.